feed,title,long_url,short_url
Benzinga,AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne,https://benzinga.com/general/biotech/22/03/26139315/anaptysbio-to-discontinue-imsidolimab-development-in-moderate-to-severe-acne,https://bit.ly/37qozT3
